Danaher Corporation $DHR Stock Sold by Curated Wealth Partners LLC

Curated Wealth Partners LLC decreased its position in shares of Danaher Corporation (NYSE:DHR) by 96.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,883 shares of the conglomerate’s stock after selling 241,076 shares during the quarter. Curated Wealth Partners LLC’s holdings in Danaher were worth $1,968,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in DHR. Marquette Asset Management LLC boosted its stake in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after buying an additional 73 shares during the period. N.E.W. Advisory Services LLC purchased a new stake in shares of Danaher in the second quarter valued at about $25,000. Main Street Group LTD purchased a new stake in shares of Danaher in the first quarter valued at about $25,000. Field & Main Bank acquired a new position in Danaher during the 2nd quarter worth approximately $29,000. Finally, Evolution Wealth Management Inc. lifted its holdings in shares of Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Strategic NVIDIA collaboration: Danaher and NVIDIA are combining NVIDIA’s accelerated-computing and AI technologies with Danaher’s scientific instruments, laboratory automation, workflow software and life-sciences expertise. The initiative is intended to advance autonomous science and accelerate drug discovery and other laboratory research, potentially supporting long-term growth in Danaher’s life-sciences businesses. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: AI-powered laboratory expansion: Danaher reportedly plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations targeted for early 2027. Although the announcement had limited immediate market impact, it reinforces the company’s positioning in laboratory automation and AI-enabled scientific workflows. How to Invest in AI Drug Discovery
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong earnings-surprise history and currently has favorable Earnings ESP and consensus-estimate factors for its next quarterly report. Analysts expect earnings growth, which may support sentiment ahead of the results. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Upcoming earnings remain the key catalyst: Danaher is projected to announce quarterly results on Wednesday. The current reports point to a possible beat, but they do not provide new reported financial results; the stock’s next move will depend on actual revenue, earnings and forward guidance. Danaher Projected to Announce Earnings

Danaher Stock Up 3.0%

Shares of Danaher stock traded up $6.82 on Thursday, hitting $231.51. 2,475,640 shares of the company’s stock traded hands, compared to its average volume of 4,446,832. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average is $212.92 and its 200 day moving average is $195.39. The stock has a market cap of $162.75 billion, a P/E ratio of 41.09, a PEG ratio of 2.80 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter last year, the company posted $0.77 earnings per share. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Analyst Ratings Changes

Several equities research analysts have commented on DHR shares. Wells Fargo & Company decreased their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Barclays boosted their target price on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Morgan Stanley raised their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group initiated coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective on the stock. Finally, Stifel Nicolaus reduced their price target on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.